AR074499A1 - Carboxamidas heterobiciclicas como inhibidoras de cinasas - Google Patents
Carboxamidas heterobiciclicas como inhibidoras de cinasasInfo
- Publication number
- AR074499A1 AR074499A1 ARP090104731A ARP090104731A AR074499A1 AR 074499 A1 AR074499 A1 AR 074499A1 AR P090104731 A ARP090104731 A AR P090104731A AR P090104731 A ARP090104731 A AR P090104731A AR 074499 A1 AR074499 A1 AR 074499A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- hydrogen
- mono
- group
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Chemical group 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- -1 C1-6-sulfonyl alkyl Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Composiciones farmacéuticas que comprenden un compuesto de la fórmula (1), y al uso de un compuesto de la fórmula (1) para la preparación de composiciones farmacéuticas para utilizarse en el tratamiento de enfermedades dependientes de la cinasa de proteína, en especial de enfermedades proliferativas, tal como en el tratamiento de enfermedades tumorales y enfermedades neovasculares oculares. Reivindicación 1: Un compuesto de la fórmula (1) o una sal del mismo, en donde R1 es hidrógeno o alquilo C1-6; R2 es hidrógeno o alquilo C1-6; R3 es hidrógeno o alquilo C1-6; R4 es hidrógeno o alquilo C1-6; o R2 y R4, tomados en combinación, forman un enlace; R5 es hidrógeno, alquilo C1-6, o halógeno; R6 representa 0, 1 o 2 residuos independientemente seleccionados en cada presentación a partir de halógeno, o alquilo C1-6; R7 es hidrógeno o alquilo C1-6; X es O o S; Z1 y Z2 se seleccionan independientemente a partir del grupo que consiste en N y CR8; R8 y R10 se seleccionan independientemente a partir del grupo que consiste en hidrógeno y alquilo C1-6; R9 se selecciona a partir del grupo que consisto en (CR11R12)nNR13R14, (CR11R12)nheterociclo, (CR11R12)nOR15, (CR11R12)nC(O)ER13, y (CR11R12)nS(O)mR17; o R8 y R9, tomados en combinación, junto con los átomos con los que están unidos, forman un anillo heterocíclico saturado de 4 a 7 miembros que tiene 1 ó 2 heteroátomos del anillo seleccionados a partir de N, O o S, cuyo anillo heterocíclico está sustituido con 0, 1 o 2 residuos seleccionados independientemente a partir del grupo que consiste en oxo, alquilo C1-6, halo-alquilo C1-6, alcoxilo C1-6, halo-alcoxilo C1-6, halógeno, hidroxilo, amino, hidroxi-alquilo C1-6, amino-alquilo C1-6, mono- y di-alquilo C1-6-amino-alquilo C1-6, cicloalquilo C3-7-alquilo C1-4, hetero-cicloalquilo C1-4, alcanoílo C1-6, mono- y di-alquilo C1-6-amino, amino-carbonilo, mono- y di-alquilo C1-6-amino-carbonilo, alcoxilo C1-6-carbonilo, alquilo C1-6-sulfonilo, amino-sulfonilo, y mono- y di-alquilo C1-6-amino-sulfonilo; Ar2 se selecciona a partir del grupo que consiste en fenilo, naftilo, un heteroarilo monocíclico o bicíclico, y heterociclo bicíclico o tricíclico, en donde cada residuo de heteroarilo o heterociclo tiene 1, 2, 3 o 4 heteroátomos del anillo seleccionados a partir de N, O o S, y en donde el grupo fenilo, naftilo, heteroarilo o heterociclo está insustituido o sustituido por 1, 2, o 3 grupos independientemente seleccionados a partir de alquilo C1-8, halo-alquilo C1-8, hidroxi-alquilo C1-6, alcoxilo C1-8, halo-alcoxilo C1-8, halógeno, hidroxilo, amino, amino-alquilo C1-6, mono- y di-alquilo C1-6-amino-alquilo C1-6, mono- y di-alquilo C1-6-amino, CO2-alquilo C1-6, fenil-alquilo C0-4, cicloalquilo C3-7-alquilo C0-4, cicloalquilo espirocíclico C3-7, amino-sulfonilo, y mono- y di-alquilo C1-6-amino-sulfonilo; m es 0, 1, o 2; n es 0, 1, 2, o 3; E está ausente, o es O o NR18: R11, R12, y R18 son iguales o diferentes, y se seleccionan independientemente en cada presentación a partir del grupo que consiste en hidrógeno y alquilo C1-4; y R13, R14, R15, R16 y R17 se seleccionan independientemente en cada presentación a partir del grupo que consiste en hidrógeno, alquilo C1-6, alcanoílo C1-6, cicloalquilo C3-6, fenilo y heterociclo, cada uno de los cuales está sustituido con 0, 1 o 2 residuos seleccionados independientemente a partir de alquilo C1-4, alcoxilo C1-4, halógeno, hidroxilo, amino, y mono- y di-alquilo C1-6-amino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20124308P | 2008-12-09 | 2008-12-09 | |
| US23334109P | 2009-08-12 | 2009-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074499A1 true AR074499A1 (es) | 2011-01-19 |
Family
ID=42034535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104731A AR074499A1 (es) | 2008-12-09 | 2009-12-07 | Carboxamidas heterobiciclicas como inhibidoras de cinasas |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US8242125B2 (es) |
| EP (1) | EP2376478B1 (es) |
| JP (1) | JP5580330B2 (es) |
| KR (1) | KR101345956B1 (es) |
| CN (2) | CN103193773B (es) |
| AR (1) | AR074499A1 (es) |
| AU (1) | AU2009326110B9 (es) |
| BR (1) | BRPI0922552A2 (es) |
| CA (1) | CA2745922C (es) |
| CL (1) | CL2011001378A1 (es) |
| CO (1) | CO6382119A2 (es) |
| CR (1) | CR20110270A (es) |
| CU (1) | CU24097B1 (es) |
| CY (1) | CY1119091T1 (es) |
| DK (1) | DK2376478T3 (es) |
| EA (1) | EA019681B1 (es) |
| EC (1) | ECSP11011113A (es) |
| ES (1) | ES2633959T3 (es) |
| HN (1) | HN2011001593A (es) |
| HR (1) | HRP20171075T1 (es) |
| HU (1) | HUE035292T2 (es) |
| IL (1) | IL213068A (es) |
| JO (1) | JO3265B1 (es) |
| LT (1) | LT2376478T (es) |
| MX (1) | MX2011006093A (es) |
| MY (1) | MY155649A (es) |
| NZ (2) | NZ601656A (es) |
| PE (1) | PE20110835A1 (es) |
| PL (1) | PL2376478T3 (es) |
| PT (1) | PT2376478T (es) |
| RS (1) | RS56076B1 (es) |
| SG (1) | SG171784A1 (es) |
| SI (1) | SI2376478T1 (es) |
| SV (1) | SV2011003939A (es) |
| TN (1) | TN2011000263A1 (es) |
| TW (1) | TWI429640B (es) |
| UY (1) | UY32302A (es) |
| WO (1) | WO2010066684A2 (es) |
| ZA (1) | ZA201103759B (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR20140008303A (ko) * | 2010-10-27 | 2014-01-21 | 노파르티스 아게 | 안구 혈관 질환의 치료를 위한 투여 요법 |
| CN102786469B (zh) * | 2011-05-18 | 2016-09-14 | 中国医学科学院药物研究所 | 邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| KR20150003903A (ko) * | 2012-05-04 | 2015-01-09 | 노파르티스 아게 | 보체 경로 조절제 및 그의 용도 |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR101315227B1 (ko) * | 2012-05-30 | 2013-10-07 | 엘지디스플레이 주식회사 | 터치스크린 일체형 표시장치 및 그 구동 방법 |
| MX2014015738A (es) * | 2012-06-28 | 2015-08-06 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la senda del complemento. |
| JP6209605B2 (ja) * | 2012-06-28 | 2017-10-04 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| JP6155332B2 (ja) * | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| JP6273274B2 (ja) * | 2012-06-28 | 2018-01-31 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| ES2712190T3 (es) * | 2012-06-28 | 2019-05-09 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| WO2014002052A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| EA201590200A1 (ru) * | 2012-07-12 | 2015-08-31 | Новартис Аг | Модуляторы пути активации комплемента и их применение |
| CN103570616B (zh) * | 2012-07-18 | 2017-10-20 | 中国医学科学院药物研究所 | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| JP6387391B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体 |
| CN104072481B (zh) * | 2013-03-28 | 2016-08-17 | 宁波市方昌医药有限公司 | 一种抗血管新生化合物 |
| US20150018376A1 (en) * | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| US10174006B2 (en) * | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9771351B2 (en) | 2013-07-29 | 2017-09-26 | Kyowa Hakko Kirin Co., Ltd. | Wnt signaling inhibitor |
| EP3089963A1 (en) | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
| US20160351119A1 (en) * | 2014-02-06 | 2016-12-01 | Joled Inc. | Display apparatus |
| JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−アミノピリジン誘導体 |
| RU2701188C2 (ru) * | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
| EP3317258A4 (en) * | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF |
| DK3322706T3 (da) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| JP6857651B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体 |
| CA3002489C (en) | 2015-11-06 | 2023-11-07 | F.Hoffmann-La Roche Ag | Indolin-2-one derivatives |
| CN108349942B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物 |
| WO2017076842A1 (en) | 2015-11-06 | 2017-05-11 | F. Hoffmann-La Roche Ag | Indolin-2-one derivatives |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| RS65988B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Postupak lečenja pedijatrijskih karcinoma |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| EP3525819A1 (en) | 2016-10-14 | 2019-08-21 | Novartis AG | Methods for treating ocular disease using inhibitors of csf-1r |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN108586454B (zh) * | 2018-02-13 | 2021-02-26 | 沈阳药科大学 | 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途 |
| CN110386892B (zh) * | 2018-04-16 | 2020-08-18 | 新发药业有限公司 | 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| KR102545594B1 (ko) | 2018-07-31 | 2023-06-21 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| US20220213064A1 (en) * | 2019-04-12 | 2022-07-07 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
| WO2021134004A1 (en) | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| EP4186894B1 (en) * | 2020-08-11 | 2024-12-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Fgfr inhibitor compound and use thereof |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| IL314186A (en) | 2022-01-24 | 2024-09-01 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
| US20250223277A1 (en) | 2022-04-01 | 2025-07-10 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001058899A1 (en) | 2000-02-09 | 2001-08-16 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| WO2002032872A1 (fr) * | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| PE20040522A1 (es) * | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| MXPA05001536A (es) * | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| AR041992A1 (es) * | 2002-11-06 | 2005-06-08 | Smithkline Beecham Corp | Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0420520D0 (en) * | 2004-09-15 | 2004-10-20 | Novartis Ag | Organic compounds |
| GB0421525D0 (en) * | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| US20090286803A1 (en) | 2006-04-07 | 2009-11-19 | Manley Paul W | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor |
| EA201000201A1 (ru) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2009
- 2009-12-06 JO JOP/2009/0466A patent/JO3265B1/ar active
- 2009-12-07 JP JP2011540046A patent/JP5580330B2/ja active Active
- 2009-12-07 PL PL09774876T patent/PL2376478T3/pl unknown
- 2009-12-07 UY UY0001032302A patent/UY32302A/es not_active Application Discontinuation
- 2009-12-07 CA CA2745922A patent/CA2745922C/en not_active Expired - Fee Related
- 2009-12-07 WO PCT/EP2009/066540 patent/WO2010066684A2/en not_active Ceased
- 2009-12-07 KR KR1020117015822A patent/KR101345956B1/ko not_active Expired - Fee Related
- 2009-12-07 DK DK09774876.8T patent/DK2376478T3/en active
- 2009-12-07 PT PT97748768T patent/PT2376478T/pt unknown
- 2009-12-07 MY MYPI2011002414A patent/MY155649A/en unknown
- 2009-12-07 NZ NZ601656A patent/NZ601656A/xx not_active IP Right Cessation
- 2009-12-07 MX MX2011006093A patent/MX2011006093A/es active IP Right Grant
- 2009-12-07 CN CN201310101393.0A patent/CN103193773B/zh active Active
- 2009-12-07 LT LTEP09774876.8T patent/LT2376478T/lt unknown
- 2009-12-07 SI SI200931684A patent/SI2376478T1/sl unknown
- 2009-12-07 BR BRPI0922552A patent/BRPI0922552A2/pt not_active IP Right Cessation
- 2009-12-07 NZ NZ593030A patent/NZ593030A/xx not_active IP Right Cessation
- 2009-12-07 US US12/632,396 patent/US8242125B2/en active Active
- 2009-12-07 AR ARP090104731A patent/AR074499A1/es unknown
- 2009-12-07 CU CU2011000129A patent/CU24097B1/es active IP Right Grant
- 2009-12-07 HU HUE09774876A patent/HUE035292T2/en unknown
- 2009-12-07 RS RS20170576A patent/RS56076B1/sr unknown
- 2009-12-07 PE PE2011001180A patent/PE20110835A1/es not_active Application Discontinuation
- 2009-12-07 EP EP09774876.8A patent/EP2376478B1/en active Active
- 2009-12-07 SG SG2011036878A patent/SG171784A1/en unknown
- 2009-12-07 CN CN200980156323.7A patent/CN102307870B/zh active Active
- 2009-12-07 EA EA201100873A patent/EA019681B1/ru not_active IP Right Cessation
- 2009-12-07 HR HRP20171075TT patent/HRP20171075T1/hr unknown
- 2009-12-07 AU AU2009326110A patent/AU2009326110B9/en not_active Ceased
- 2009-12-07 ES ES09774876.8T patent/ES2633959T3/es active Active
- 2009-12-08 TW TW098141904A patent/TWI429640B/zh not_active IP Right Cessation
-
2011
- 2011-05-23 CR CR20110270A patent/CR20110270A/es unknown
- 2011-05-23 ZA ZA2011/03759A patent/ZA201103759B/en unknown
- 2011-05-23 TN TN2011000263A patent/TN2011000263A1/fr unknown
- 2011-05-23 IL IL213068A patent/IL213068A/en not_active IP Right Cessation
- 2011-06-07 EC EC2011011113A patent/ECSP11011113A/es unknown
- 2011-06-08 CL CL2011001378A patent/CL2011001378A1/es unknown
- 2011-06-09 SV SV2011003939A patent/SV2011003939A/es unknown
- 2011-06-09 HN HN2011001593A patent/HN2011001593A/es unknown
- 2011-06-10 CO CO11072268A patent/CO6382119A2/es active IP Right Grant
-
2012
- 2012-06-05 US US13/488,760 patent/US8431584B2/en active Active
- 2012-09-13 US US13/613,019 patent/US8492393B2/en active Active
- 2012-09-13 US US13/613,034 patent/US8486954B2/en active Active
- 2012-09-13 US US13/613,062 patent/US8501756B2/en active Active
- 2012-09-13 US US13/613,053 patent/US8541432B2/en active Active
-
2017
- 2017-07-19 CY CY20171100772T patent/CY1119091T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074499A1 (es) | Carboxamidas heterobiciclicas como inhibidoras de cinasas | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR071717A1 (es) | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR063099A1 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR062785A1 (es) | Compuestos de 4-metilpiridopirimidinona, composiciones farmaceuticas que los contienen y usos en estados patologicos asociados al crecimiento anormal celular,tal como cancer. | |
| AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
| AR074543A1 (es) | Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| AR092288A1 (es) | Ligandos del receptor ep1 | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR087563A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |